{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:49:41Z","timestamp":1779317381300,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005129D122\u2013 Milinic"],"award-info":[{"award-number":["005129D122\u2013 Milinic"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007287"],"award-info":[{"award-number":["T32HL007287"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NR020470"],"award-info":[{"award-number":["R01NR020470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials in cystic fibrosis (CF) disproportionately over-represent non-Hispanic, White individuals. Barriers and facilitators to enrolling racially and ethnically minoritized individuals with CF are not well understood. This study explored research coordinator (RC) perspectives on recruitment and enrollment of minoritized people with CF (PwCF) into clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional survey was administered to RCs in the CF Therapeutics Development Network (CF TDN), eliciting perceived barriers and facilitators to inclusion of minoritized PwCF in clinical research. Respondents were categorized based on their self-reported experience discussing and successfully enrolling minoritized PwCF into clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 48 respondents, the majority (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931, 64%) had little to no experience discussing CF clinical trials with minoritized PwCF. Respondents who had a moderate or great deal of experience (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920, 91%) identified that having a trusted clinical team member first introduce the study to PwCF as the most common strategy for recruitment. Experienced respondents also identified the importance of having team members who speak the same language or are the same culture as the minoritized PwCF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917, 35%). Respondents who had little to no experience successfully enrolling minoritized PwCF into clinical trials cited low numbers of minoritized patients at their study center as an important consideration (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931, 47%). Among all levels of experience, respondents emphasized language barriers in enrollment including need for adequate translation services and printed materials in the PwCF\u2019s primary language.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study identified modifiable barriers that may be addressed at the level of trial design and study center. This study highlights the importance of trusted, culturally competent research teams and underscores the importance of language accessibility in recruitment in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-025-03707-9","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:49:57Z","timestamp":1751615397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Research coordinators\u2019 perspectives on recruitment of minoritized people with cystic fibrosis into clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Tijana","family":"Milinic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Burdis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Burks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Elizabeth","family":"Jarosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha G.","family":"Kapnadak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"3707_CR1","volume-title":"Registry 2022 annual data report","author":"Cystic Fibrosis Foundation Patient","year":"2022","unstructured":"Cystic Fibrosis Foundation Patient. Registry 2022 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2022."},{"issue":"2","key":"3707_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0022-3476(98)70441-X","volume":"132","author":"A Hamosh","year":"1998","unstructured":"Hamosh A, FitzSimmons SC, Macek M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998;132(2):255\u20139. PMID: 9506637.","journal-title":"J Pediatr"},{"issue":"12","key":"3707_CR3","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/ppul.23884","volume":"52","author":"ME McGarry","year":"2017","unstructured":"McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol. 2017;52(12):1550\u20137. PMCID: PMC5693693.","journal-title":"Pediatr Pulmonol"},{"key":"3707_CR4","doi-asserted-by":"crossref","unstructured":"Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California. CHEST J. 2016;149(2):380\u20139. PMCID: PMC5831377.","DOI":"10.1378\/chest.14-2189"},{"issue":"6","key":"3707_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ppul.21037","volume":"44","author":"KD Watts","year":"2009","unstructured":"Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatr Pulmonol. 2009;44(6):594\u2013601. PMID: 19437506.","journal-title":"Pediatr Pulmonol"},{"key":"3707_CR6","doi-asserted-by":"crossref","unstructured":"Rho J, Ahn C, Gao A, Sawicki GS, Keller A, Jain R. Disparities in mortality of Hispanic cystic fibrosis patients in the united States: A National and regional cohort study. Am J Respir Crit Care Med. 2018;198(8):1055\u20131063.","DOI":"10.1164\/rccm.201711-2357OC"},{"key":"3707_CR7","doi-asserted-by":"crossref","unstructured":"McGarry ME, McColley SA. Minorities are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Annals ATS. Published online July 13, 2016:AnnalsATS.201603-192BC. PMCID: PMC5122490.","DOI":"10.1513\/AnnalsATS.201603-192BC"},{"issue":"1","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1164\/rccm.200502-273OC","volume":"173","author":"CH Goss","year":"2006","unstructured":"Goss CH, Rubenfeld GD, Ramsey BW, Aitken ML. Clinical trial participants compared with nonparticipants in cystic fibrosis. Am J Respir Crit Care Med. 2006;173(1):98\u2013104. PMCID: PMC2662984.","journal-title":"Am J Respir Crit Care Med"},{"key":"3707_CR9","doi-asserted-by":"crossref","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: A cohort study. The Lancet Regional Health - Americas. 2022;11:100252. PMCID: PMC9302767.","DOI":"10.1016\/j.lana.2022.100252"},{"key":"3707_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.28575","volume":"120","author":"MS Chen Jr","year":"2014","unstructured":"Chen MS Jr, Lara PN, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH revitalization act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014;120:1091\u20136. PMCID: PMC3980490.","journal-title":"Cancer"},{"issue":"5","key":"3707_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","volume":"44","author":"LT Clark","year":"2019","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148\u201372. PMID: 32723500.","journal-title":"Curr Probl Cardiol"},{"key":"3707_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fcell.2019.00074","volume":"7","author":"TC Davis","year":"2019","unstructured":"Davis TC, Arnold CL, Mills G, Miele L. A qualitative study exploring barriers and facilitators of enrolling underrepresented populations in clinical trials and biobanking. Front Cell Dev Biol. 2019;7:74. https:\/\/doi.org\/10.3389\/fcell.2019.00074. PMID: 31114788; PMCID: PMC6502895.","journal-title":"Front Cell Dev Biol"},{"issue":"15","key":"3707_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMe2114651","volume":"385","author":"The Editors","year":"2021","unstructured":"The Editors. Striving for diversity in research studies. N Engl J Med. 2021;385(15):1429\u201330. PMID: 34516052.","journal-title":"N Engl J Med"},{"issue":"12","key":"3707_CR14","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1200\/OP.20.01093","volume":"17","author":"M Roy","year":"2021","unstructured":"Roy M, Purington N, Liu M, Blayney DW, Kurian AW, Schapira L, Disparities in Health Care Engagement Among Patients With Breast Cancer. Limited english proficiency and. JCO Oncol Pract. 2021;17(12):e1837\u201345. https:\/\/doi.org\/10.1200\/OP.20.01093. Epub 2021 Apr 12. PMID: 33844591; PMCID: PMC9810131.","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"3707_CR15","first-page":"e17202","volume":"13","author":"AR Keruakous","year":"2021","unstructured":"Keruakous AR, Day S, Garcia-Ramiu K, Yarbrough M, Asch AS. Research staff perspectives on Cancer clinical trials and barriers to recruitment: A qualitative research. Cureus. 2021;13(8):e17202. PMID: 34540430; PMCID: PMC8439775.","journal-title":"Cureus"},{"key":"3707_CR16","doi-asserted-by":"publisher","unstructured":"Otado J, Kwagyan J, Edwards D, Ukaegbu A, Rockcliffe F, Osafo N. Culturally Competent Strategies for Recruitment and Retention of African American Populations into Clinical Trials. Clin Transl Sci. 2015;8(5):460-6. https:\/\/doi.org\/10.1111\/cts.12285. Epub 2015 May 14. PMID: 25974328; PMCID: PMC4626379.","DOI":"10.1111\/cts.12285"},{"key":"3707_CR17","doi-asserted-by":"publisher","unstructured":"Dobra R, Elborn JS, Madge S et al. Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study. Journal of Cystic Fibrosis. 2021;20(6):986\u2013993. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.021. PMID: 33895096.","DOI":"10.1016\/j.jcf.2021.03.021"},{"issue":"6","key":"3707_CR18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.25285","volume":"56","author":"ME McGarry","year":"2021","unstructured":"McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496\u2013503. PMCID: PMC8137541.","journal-title":"Pediatr Pulmonol"},{"key":"3707_CR19","doi-asserted-by":"crossref","unstructured":"Velez MA, Glenn BA, Garcia-Jimenez M, Cummings AL, Lisberg A, Na\u00f1ez A, Radwan Y, Lind-Lebuffe JP, Brodrick PM, Li DY, Fernandez-Turizo MJ, Gower A, Lindenbaum M, Hegde M, Brook J, Grogan T, Elashoff D, Teitell MA, Garon EB. Consent document translation expense hinders inclusive clinical trial enrolment. Nature. 2023 Aug 2. PMID: 37532930.","DOI":"10.1038\/s41586-023-06382-0"},{"key":"3707_CR20","doi-asserted-by":"crossref","unstructured":"Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M. The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing. J Mol Diagn. 2016;18(1):39\u201350. doi: 10.1016\/j.jmoldx.2015.07.005. PMID: 26708955.","DOI":"10.1016\/j.jmoldx.2015.07.005"},{"key":"3707_CR21","doi-asserted-by":"publisher","unstructured":"Watts KD, Layne B, Harris A, McColley SA. Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. J Genet Couns. 2012;21(5):671-5. https:\/\/doi.org\/10.1007\/s10897-012-9481-2. Epub 2012 Feb 4. PMID: 22311127.","DOI":"10.1007\/s10897-012-9481-2"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03707-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:50:00Z","timestamp":1751615400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03707-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03707-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5195002\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Washington Human Subjects Division IRB approved this study (Study #00018252). The IRB provided a waiver of documentation of informed consent since the study was determined to be minimal in risk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}